Pulmatrix (PULM)
(Delayed Data from NSDQ)
$2.01 USD
+0.22 (12.29%)
Updated Sep 13, 2024 03:13 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
PULM 2.01 +0.22(12.29%)
Will PULM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PULM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PULM
Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Lags Revenue Estimates
PULM: What are Zacks experts saying now?
Zacks Private Portfolio Services
UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
Amicus Therapeutics (FOLD) Reports Q3 Loss, Misses Revenue Estimates
Other News for PULM
Pulmatrix GAAP EPS of -$1.59, revenue of $1.6M
PULM Stock Earnings: Pulmatrix Reported Results for Q2 2024
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix reports Q2 EPS ($1.59) vs. ($1.04) last year
Pulmatrix Announces Executive Changes and New Interim CEO